Twelve biopharma execs collected nearly $1B in golden parachutes from 2025–26 M&A deals, led by Cidara's Jeffrey Stein ($221M) and Arcellx's Rami Elghandour ($137M).
A dozen biotech executives took home nearly $1 billion worth of exit packages from selling their companies, an Endpoints News analysis found.
The drug industry …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Health Care Up Amid Multibillion Dollar Oncology Deals - Health Care Roundup
Gilead and Merck's latest trial success and flop
Parabilis sets a record with a $670M biotech IPO
Small Biotech Catapults To Record High On $10.6 Billion Deal
Novartis doubles down on molecular glue strategy
‘Not simply saving cost’: Inside Astellas CEO’s 5-year strategy to counter Xtandi’s patent cliff
Catalyst is already the fourth biotech acquisition this month, continuing an acceleration of bigger-ticket deals that’s put 2026…
Biopharma's 10 highest-paid CSOs and CMOs in 2025: Lilly's Dan Skovronsky led at $17.8M, with nine others topping $10M.
Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking in…
Endpoints launches its annual biopharma pay project; Andrew Dunn and Drew Armstrong break down CEO compensation live on June 9,…
After some six years at the post, Amgen’s finance chief is telegraphing his exit from the California pharma by early next year. …
Megadeals are largely missing in an otherwise healthy M&A environment for biopharma.
